25 July 2024   Hongene Biotech challenged ChemGenes’ patent after litigation withdrawn | Judges said all challenged claims were unpatentable.

Latest Features

Biotechnology
AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Americas
Brazil’s updated regulations for its flagship partnerships programme marks a renewed effort to strengthen the nation's health sector, says Rob Rodrigues of RNA Law.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
Biotechnology
As artificial intelligence creates a complex legal landscape for healthcare and medtech, Janine Swarbrick of HGF explores two case studies that shed light on how to claim an AI invention.
Plant Varieties
Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP.
All features


More News

18 July 2024   Guidance says use of AI in inventing does not affect how patent claims are assessed for eligibility | Emphasis placed on evaluating inventions themselves rather than the method of creation | Updates include new examples to assist examiners in evaluating AI-related patent claims.
16 July 2024   New bill anticipated to depart from previous government’s light-touch approach to AI regulation | Attorneys fear “onerous or conflicting” requirements on pharma and biotech companies.
16 July 2024   UPC’s Munich Central Division revokes Amgen's patent | Decision stems from a revocation action initiated by Sanofi last year | Court's ruling focused on interpretations of patent claims and principles of inventive step.
16 July 2024   Firm adds new chair of Hatch-Waxman & Biologics Practice is an FDA and pharma litigation expert who will ‘provide clarity in an uncertain post-Chevron world’ | Shareholder brings extensive trial and appellate experience in automotive industry.
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.
11 July 2024   Top ten UPC law firms handled over 70% of cases filed at the court | Full list of most prolific plaintiffs and defendants named.
11 July 2024   Proposed change will cut down ‘patent thickets’ says FTC | Biotech firms say changes will damage innovation.
More news